Intrapericardial therapeutics: A pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery

被引:20
|
作者
Ujhelyi, MR
Hadsall, KZ
Euler, DE
Mehra, R
机构
[1] Medtron CRM Res, Minneapolis, MN 55432 USA
[2] Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA
关键词
pericardium; procainamide; pharmacokinetics; atrial fibrillation; ventricular fibrillation; electrophysiology; antiarrhythmic therapy; conduction velocity; refractory period;
D O I
10.1046/j.1540-8167.2002.00605.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Procainamide delivery into the pericardial space may produce a greater and more prolonged electrophysiologic effect, particularly in thin superficial atrial tissue, compared with intravenous delivery. Methods and Results: Swine were randomized to sequential procainamide doses delivered intravenously (n = 6) or into the pericardial space (n = 7). The cumulative pericardial doses were 0.5, 1.5, and 3.5 mg/kg, and the intravenous doses were 2, 10, and 26 mg/kg. Pericardial procainamide prolonged right atrial effective refractory period from baseline by 22% (P < 0.01) but only at the 3.5 mg/kg cumulative dose. This dose slowed interatrial conduction time by 14% (P < 0.05) and raised atrial fibrillation threshold by 70 mA (P < 0.05). Pericardial procainamide had minimal effect on ventricular electrophysiology. Similar results occurred with a single 2 mg/kg pericardial dose in a closed chest model. Intravenous 10 and 26 mg/kg cumulative doses prolonged atrial effective refractory period from baseline by 24% and 18% (P < 0.01), respectively. The 26 mg/kg cumulative intravenous dose slowed interatrial and atrial-ventricular conduction times by 27% and 17%, respectively (P < 0.05), raised atrial fibrillation threshold, and slowed ventricular conduction time by 29% (P < 0.05). Pericardial procainamide produced pericardial fluid concentrations ranging from 250 to 1,500 mug/mL, but plasma concentrations were <1 mug/mL. Intravenous procainamide doses produced pericardial fluid concentrations similar to plasma trough concentrations 0 to 12 mug/mL. Conclusion: The single 2 mg/kg and 3.5 mg/kg cumulative pericardial procainamide doses prolonged atrial refractoriness and raised atrial fibrillation threshold similar to the 26 mg/kg cumulative intravenous dose, but the duration of effect was similar between delivery methods. Pericardial procainamide did not affect global or endocardial ventricular electrophysiology nor was it associated with ventricular proarrhythmia.
引用
收藏
页码:605 / 611
页数:7
相关论文
共 41 条
  • [21] Evaluation of intrapericardial regenerative therapy in a porcine myocardial infarction model: comparison between free versus microencapsulated CDCs delivery
    Baez Diaz, C.
    Blanco Blazquez, V.
    Sanchez Margallo, F. M.
    Lopez, E.
    Martin, H.
    Espona-Noguera, A.
    Casado, J. G.
    Ciriza, J.
    Pedraz, J. L.
    Crisostomo, V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 310 - 310
  • [22] COMPARISON OF THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF SINGLE AND MULTIPLE DOSES OF A COMMERCIAL SLOW-RELEASE METOPROLOL FORMULATION WITH A NEW OROS DELIVERY SYSTEM
    KENDALL, MJ
    JACK, DB
    WOODS, KL
    LAUGHER, SJ
    QUARTERMAN, CP
    JOHN, VA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (03) : 393 - 398
  • [23] Comparison of pharmacodynamic and pharmacokinetic dose-response profiles between insulin detemir and NPH insulin in subjects with type 2 diabetes
    Pieber, TR
    Wutte, A
    Plank, J
    Bock, G
    Magnes, C
    Bodenlenz, M
    Endahl, L
    Draeger, E
    Jacobsen, LV
    DIABETES, 2004, 53 : A142 - A142
  • [24] Comparison of peripheral-to-central circulation delivery times between intravenous and intraosseous infusion in foals
    Tate, LP
    Berry, CR
    King, C
    EQUINE VETERINARY EDUCATION, 2003, 15 (04) : 201 - 206
  • [25] Efficient trial design for eliciting a pharmacokinetic-pharmacodynamic model-based response surface describing the interaction between two intravenous anesthetic drugs
    Short, TG
    Ho, TY
    Minto, CF
    Schnider, TW
    Shafer, SL
    ANESTHESIOLOGY, 2002, 96 (02) : 400 - 408
  • [26] A Pharmacokinetic and Alpha-4 Integrin Saturation (Pharmacodynamic) Comparison of Caucasian and Japanese Populations Receiving Intravenous 300 mg Q4W Natalizumab
    Amarante, D.
    Muralidharan, K. K.
    Subramanyam, M.
    Ho, P-R
    Nestorov, I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 337 - 337
  • [27] Pharmacokinetic-pharmacodynamic (PK-PD) correlation of ibuprofen analgesia: Comparison between ibuprofen arginate (IA) and motrin IB (MO).
    Arends, R
    Shen, D
    Desjardins, P
    Max, M
    Norwood, T
    McAuley, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII20 - PII20
  • [28] Pharmacokinetic Comparison between Regional Arterial Infusion and Intravenous Injection with 5-Fluorouracil in Experimental Severe Acute Pancreatitis
    Xie, Yangyun
    Zhou, Ziye
    Li, Mei
    Duan, Wei
    Lv, Wanzhi
    Sun, Hongwei
    Zhou, Mengtao
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (04): : 477 - 483
  • [29] Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
    Jeon, Inseung
    Oh, Jaeseong
    Kwon, Yu-Kyung
    Yoon, Seo Hyun
    Cho, Joo-Youn
    Jang, In-Jin
    Yu, Kyung-Sang
    Lee, SeungHwan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 1735 - 1747
  • [30] A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Ulrike Hövelmann
    Eric Zijlstra
    Kirstine Stender-Petersen
    Jacob Bonde Jacobsen
    Hanne Haahr
    Drugs & Aging, 2017, 34 : 29 - 38